Why is Vivanza Biosci. falling/rising?

As of 23-Jun, Vivanza Biosciences Ltd is currently priced at 2.21, reflecting an increase of 0.06 or 2.79%. The stock has shown a positive performance today, outperforming its sector by 3.25% and has experienced consecutive gains over the last two days, rising a total of 6.25%. However, despite this recent uptick, the stock has significantly underperformed over the longer term, with a year-to-date decline of 36.49% and a staggering 61.70% drop over the past year. The company is facing substantial challenges, including operating losses, a high debt-to-EBITDA ratio of 5.34, and negative results for the last three consecutive quarters, which indicate weak long-term fundamental strength and low profitability.
In the broader market context, while the stock has made slight gains recently, it has still underperformed against the benchmark, with a 1-week return of -6.75% compared to a slight increase of 0.12% in the Sensex. This consistent underperformance over the past three years, coupled with a significant decline in investor participation—evidenced by a 51.99% drop in delivery volume—suggests a lack of confidence among investors. The liquidity of the stock remains adequate for trading, but the overall sentiment is cautious due to the company's financial instability and negative EBITDA, which contribute to its classification as a strong sell.